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revealed a complex pharmacology of DM with mechanisms beyond blockade of N-methyl-D-aspartate (NMDA)
receptors and inhibition of glutamate excitotoxicity, likely contributing to its pharmacological activity and clinical
potential.
DM is rapidlymetabolized to dextrorphan, which has hampered the exploration of DM therapy separate from its
metabolites. Coadministration of DM with a low dose of quinidine inhibits DM metabolism, yields greater bio-
availability and enables more speciﬁc testing of the therapeutic properties of DM apart from its metabolites.
The development of thedrug combinationDMhydrobromide and quinidine sulfate (DM/Q),with subsequent ap-
proval by the US Food andDrug Administration for pseudobulbar affect, led to renewed interest in understanding
DM pharmacology.
This review summarizes the interactions of DMwith brain receptors and transporters and also considers its met-
abolic and pharmacokinetic properties. To assess the potential clinical relevance of these interactions, we provide
an analysis comparing DM activity from in vitro functional assays with the estimated free drug DM concentra-
tions in the brain following oral DM/Q administration. The ﬁndings suggest that DM/Q likely inhibits serotonin
and norepinephrine reuptake and also blocks NMDA receptors with rapid kinetics. Use of DM/Q may also
antagonize nicotinic acetylcholine receptors, particularly those composed of α3β4 subunits, and cause agonist
activity at sigma-1 receptors.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Dextromethorphan (DM)has long been used as an over-the-counter
cough suppressant, though the molecular mechanism to suppress
coughing is not well established (Kamei et al., 1989; Brown et al.,
2004; Kim et al., 2009; Canning & Mori, 2010; Young & Smith, 2011).
DMhas amulti-faceted pharmacology and has interactionswith seroto-
nin transporters, noradrenaline (NA) transporters, sigma-1 receptors
(Sig1-R), α3β4 nicotinic acetylcholine receptors, and N-methyl-D-
aspartate receptors (NMDARs). These proteins are present in several
neurotransmitter systems that are targeted in the treatment of neuro-
logical and psychiatric disorders. Although structurally related to opioid
agonists, DMdoes not have relevant activity at opioid receptors (Kachur
et al., 1986; Gaginella et al., 1987; Redwine & Trujillo, 2003; Chen et al.,
2005). The receptor pharmacology of DM (particularly at NMDARs) has
led clinical researchers to explore its therapeutic potential in conditions
such as pain (McQuay et al., 1994; Ilkjaer et al., 2000) and epilepsy
(Fisher et al., 1990; Kimiskidis et al., 1999), as a neuroprotectant for
acute brain injury or stroke (Albers et al., 1992), and for neurodegener-
ative disorders (Walker & Hunt, 1989; Gredal et al., 1997). However,
most of these early clinical trials of DM failed to show therapeutic utility.
The lack of therapeutic response may have been inﬂuenced by low and
variable bioavailability of DM when administered alone because of its
rapid ﬁrst-pass metabolism and subsequent elimination.
In order to increase plasma concentrations and bioavailability in the
central nervous system (CNS), DMwas combined with quinidine (Q), a
potent inhibitor of the cytochrome P450 (CYP) liver enzyme CYP2D6,
which is the primary enzyme involved in DMmetabolism (Fig. 1). The
combined dextromethorphan and quinidine formulation is referred to
as DM/Q. The addition of quinidine in the DM/Q combined dosage
form causes substantial changes in the circulating amounts of both dex-
tromethorphan and dextrorphan (DX), with the predominant active
compound changing from dextrorphan when DM is given alone, as
with cough suppressants, to dextromethorphan when given as DM/Q.
For example, the ratio of circulating free DX to free DM is 6.4-fold inFig. 1. Dextromethorphan metabolism. Dextromethorphan in extensive metabolizers is rapidly
treated with quinidine, this metabolism is mostly blocked. Subsequently, most dextrorphan
relatively minor pathway. Both 3-methoxymorphinan and dextrorphan are further metab
particularly at NMDA receptors. UGT — uridine 5′-diphospho-glucuronosyltransferase; DM
Isoherranen (2012).favor of dextrorphanwith DM given alone but is 14-fold in favor of dex-
tromethorphan with DM/Q (see Fig. 2B and further explanation in
Section 2, Dextromethorphan metabolism and pharmacokinetics).
Pharmacokinetic studies evaluating this combination demonstrated
large increases in DM bioavailability in the presence of quinidine,
and this led to renewed interest in clinical trials culminating in the com-
bination of DM hydrobromide and Q sulfate (DM/Q; Nuedexta®) being
approved by the US Food and Drug Administration in 2010 and by
the European Medicines Agency in 2013 as a treatment for the neu-
rological condition, pseudobulbar affect (PBA). PBA can occur in per-
sons with neurological disorders affecting the brain or with brain
injury and is characterized by frequent, involuntary and uncontrolla-
ble laughing or crying episodes that can be incongruent with mood
or social context.
DM/Q has also shown therapeutic effects in well-controlled clinical
trials for diabetic peripheral neuropathic pain (Shaibani et al., 2012)
and agitation secondary to Alzheimer's disease (Cummings et al.,
2015). In a small pilot study, DM/Q therapy reduced the abnormally
large late auditory evoked potential (N400) produced by hearing a fa-
miliar name in patients with PBA secondary to multiple sclerosis, con-
sistent with DM/Q effects on neocortical brain activity in these
patients (Haiman et al., 2009). A preliminary retrospective case series
of patients treated for bipolar depression (Kelly & Lieberman, 2014)
and chorea of various etiologies (Ondo, 2012) also suggested this drug
combination may have therapeutic effects in these CNS disorders
(Lauterbach, 2012). The precise molecular mechanism of action of
DM/Q in each of these disparate conditions is unknown, and actions at
more than one receptor or transporter might be involved.
This review summarizes the interaction of DM with various CNS
receptors and transporters and also considers its rapid ﬁrst-passmetab-
olism to dextrorphan (DX). In addition to reviewing ﬁndings in the
literature, this paper presents an original analysis of the therapeutic
relevance of DM receptor interactions based on plasma drug concentra-
tions and predicted cerebrospinal ﬂuid (CSF) concentrations using data
from clinical studies of DM/Q.metabolized (mostly in liver) to form dextrorphan. In poor metabolizers and in persons
is rapidly glucuronidated. Demethylation by CYP3A4 to form 3-methoxymorphinan is a
olized to 3-hydroxymorphinan. Dextrorphan has signiﬁcant pharmacological activity,
– dextromethorphan; Q – quinidine. Figure is adapted with permission from Lutz and
Fig. 2. Dextromethorphan and dextrorphan concentrations in human plasma with DM/Q oral administration. Healthy subjects were given 30 mg dextromethorphan (DM) plus 10 mg
quinidine to block DM metabolism daily for 7 days. Total drug in plasma was measured and free concentration in plasma was calculated. A. Plasma drug concentrations (DM and
dextrorphan, DX) were obtained at various times after dosing (time 0) on day 7. This graph shows total plasma concentrations of DM (protein-bound plus unbound, blue circles) and
DX (conjugated plus non-conjugated, orange squares). B shows free (unbound) concentrations of DM and DX based on data as measured in part A. Free DM (light blue open circles)
was calculated considering 65% DM binding to plasma proteins (Avanir Pharmaceuticals, Inc., 2010), and non-glucuronidated free DX (light orange open squares) was calculated
assuming covalently glucuronidated DX is 33 to 43-fold greater than non-glucuronidated free DX (Chen et al., 1990; Kazis et al., 1996). Data points are means from 4 subjects from an
unpublished Avanir study (13-AVR-134). Similar dosing of 30 mg DM without quinidine resulted in unbound peak DM concentrations that were 25-fold lower (blue arrow) and peak
free DX concentrations that were 4-fold greater (orange arrow), so DX represents the major active compound when quinidine is not used, while DM predominates when quinidine is
used. Unbound concentrations are assumed to be in equilibriumwith brain extracellular ﬂuid. In summary, blocking DMmetabolism changed the ratio of free DM to free DX by ~100-fold.
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In ~90% of individuals, referred to as extensive metabolizers, DM
undergoes rapid and extensive ﬁrst-pass metabolism to the major O-
demethylated metabolite dextrorphan (DX) mediated by CYP2D6
(Fig. 1). As CYP2D6 is a polymorphically expressed enzyme, some indi-
viduals lack CYP2D6 activity (poor metabolizers) and others express
varying levels of enzyme activity. In a less prominent elimination
pathway, DM undergoes N-demethylation to 3-methoxymorphinan
via CYP3A4/A5. Both DX and 3-methoxymorphinan undergo further
demethylation to 3-hydroxymorphinan.
When DM is administered by itself orally (30 mg) to extensive
metabolizers, only low plasma levels (unbound plasma concentrations
of 2 to 4 nM) are achieved due to rapid and extensive metabolism
to DX (Chen et al., 1990; Pope et al., 2004). Once DX is formed, it is
glucuronidated by uridine diphosphate-glucuronosyltransferase to
form dextrorphan-O-glucuronide, and most DX (~97 to 98%) is present
in plasma as the O-glucuronide (Chen et al., 1990; Kazis et al., 1996).
Dextrorphan-O-glucuronide is permanently charged and less perme-
able to the blood–brain barrier than unconjugated DX, and therefore is
unlikely to produce signiﬁcant pharmacological effects in the brain at
clinically used doses even though it may be present at higher
total (bound and unbound) plasma concentrations than DM. Further-
more, glucuronidated compounds usually are rapidly eliminated by
the kidneys (Wu et al., 1995). As unconjugated 3-methoxymorphinan
and 3-hydroxymorphinan (3-hydroxymorphinan is also rapidly
glucuronidated) are found at concentrations even lower than those
of DM in both extensive and poor metabolizers, their pharmacology
is not discussed in this review.
2.1. Increasing dextromethorphan exposure by blocking its metabolism
Studies in healthy human volunteers show that coadministration of
the CYP2D6 inhibitor, quinidine, decreases the rate of metabolism of
DM, thereby increasing its elimination half-life (t1/2) from ~4 h (Kazis
et al., 1996) to ~13 h (Pope et al., 2004) in volunteers with an extensive
metabolizer phenotype, allowing twice-daily administration to main-
tain consistent DM plasma concentrations. For instance, at the DM/Q
FDA-approved dosage for the treatment of PBA (DM 20 mg and quini-
dine 10 mg, administered twice daily), the maximum plasma concen-
tration (Cmax) of DM is ~51 ng/mL (66 nM unbound DM) (Pope et al.,2004; Avanir Pharmaceuticals, Inc., 2010). In contrast, in extensive
metabolizers receiving DM 30 mg without quinidine, the Cmax for DM
is only 2.9 ng/mL (3.7 nM unbound) (Pope et al., 2004). These ﬁndings
and the pharmacokinetic proﬁle for DM following administration of
DM/Q are summarized in Fig. 2. It is also important to note that the
daily dose of quinidine in DM/Q is much lower than the antiarrhythmic
dose of quinidine that is used to block cardiac sodium channels. Use of
DM/Q at approved doses (20/10 mg twice daily), results in a maximum
quinidine plasma concentration (Cmax) that is only 1% to 3% of the
concentration required for antiarrhythmic efﬁcacy.
Several clinical studies suggest that unchangedDM is responsible for
pharmacodynamic effects observed in humans following dosing with
DM plus quinidine, despite the slightly higher total plasma concentra-
tions of DX (much of which is conjugated, see Fig. 2). For example,
DM plus quinidine signiﬁcantly reduced the requirement for nonsteroi-
dal anti-inﬂammatory drugs after knee replacement surgery compared
with DM plus placebo (Ehret et al., 2013). Likewise for PBA, DM plus
quinidine demonstrated signiﬁcant efﬁcacy compared to placebo
(Panitch et al., 2006; Pioro et al., 2010), and, in a study comparing efﬁ-
cacy of DM/Q to its individual components, the combination was signif-
icantlymore effective in treating PBA than either DMor Q alone (Brooks
et al., 2004).
Limited data on DMand itsmetabolite concentrations in CSF suggest
that DM concentrations in plasma can be used to estimate free DM con-
centrations present in the extracellular ﬂuid of the brain. Measured CSF
concentrations of DM in humans (Steinberg et al., 1996; Lutz &
Isoherranen, 2012) were very close to unbound DM in plasma (Fig. 3).
The unbound DM concentration is 35% of measured humanwhole plas-
ma concentrations, as derived from 65% nonspeciﬁc binding of DM to
plasma proteins (Pope et al., 2004). When DX levels were measured in
CSF (Kazis et al., 1996), they were found to be very close to unconjugat-
ed DX in plasma. Therefore, for our analysis (detailed in Section 4), we
chose unbound DM in plasma and unconjugated DX in plasma as the
relevant concentrations for estimating pharmacological actions in the
brain.
Studies that measure both DM and DX in the CSF of humans will
be needed to determine unbound brain concentrations of DM and
DX in patients receiving DM alone or the DM plus Q combination.
Nonetheless, in vitro and in vivo data from studies that measured
free DX are tabulated in parallel in this review when information is
available.
Fig. 3. Concentrations of DM in serum and cerebrospinal ﬂuid (CSF). Serum and CSF concentrations of DM in human patients are correlated (r=0.88, P b 0.0001). CSF concentrations are
30% of those in serum (blue line), or very similar to the unbound plasma drug concentration calculatedwith 65% of DM in plasma bound to plasma proteins, as determined in vitro (Avanir
Pharmaceuticals, Inc., 2010). Data presented in the ﬁgure are from the Steinberg et al. (1996) study in neurosurgical patients given ascending doses of oral DM to a maximum tolerated
dose ranging from 0.8 to 9.6 mg/kg (40 to 480 mg for a 50 kg person). Figure is adapted with permission from Steinberg et al. (1996).
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3.1. Overview of receptor and transporter interactions
The CNS pharmacology of DM and the likely involvement of
NMDARs and Sig1-Rs were reviewed in 1989 by Tortella et al. (1989).
More recently, a preclinical pharmacology review provided a tabulated
summary of the evidence supporting the neuroprotective effects of DM
in various nonclinical models of CNS injury (Werling et al., 2007a). The
reader is referred to these reviews for additional information. Here,
evidence from an in vitro binding study of DM assessing 26 potential
binding sites (Werling et al., 2007b) is discussed, as are previously un-
published data from a second radioligand screening study (Table 1).Table 1
Radioligand binding data with dextromethorphan (DM) and dextrorphan (DX).
Receptor Ki or % inhibition DM Ki or % inhibition DX
5-HT transport 40 nM 484 nM
Sig1-R 150 nM 118 nM
NA transport 6000 nM 6200 nM
NMDAR 962 nM 148 nM
NMDAR 2120 nM 892 nM
Adrenergic α1D 830 nM NT
Adrenergic α1A 3000 nM NT
Sigma-2 11,060 nM 11,325 nM
5-HT1B/D 61% at 1000 nM 54% at 1000 nM
Adrenergic α-2 60% at 1000 nM NC
Histamine-1 NC at 1000 nM 95% at 1000 nM
Abbreviations: 5-HT — serotonin; NA — noradrenaline; NMDAR — N-methyl-D-aspartate glut
(less than 30% inhibition at 1000 nM). Data on adrenergic radioligand binding is from Avanir d
Note:Dextromethorphan did not signiﬁcantly inhibit radioligand binding at 10,000 nMat severa
These inactive binding sites for dextromethorphan include: adenosine A1, A2A, A3, adrenergicα
type, cannabinoid CB1, dopamine D1, D2S, D3, D4.2, endothelin ETA, ETB, epidermal growth fa
glutamate NMDAR agonist site, glutamate NMDAR glycine site, strychnine-sensitive glycine, his
M1, M2, M3, neuropeptide Y Y1, Y2, nicotinicα1, opiate μ, δ, κ, phorbol ester, platelet activating
P2Y, rolipram, serotonin 5-HT2A, 5-HT2B, 5-HT3, tachykinin NK1, testosterone, thyroid hormon
Note— Any functional signiﬁcance of radioligand binding activity at ~1000 nM and greater con
mation with functional tests (these data are shown in italics in the table). For example, clinica
radioligand binding of 3 nM to 440 nM (Buzzi & Moskowitz, 1991), and the selective adrene
et al., 1995).These results show that DM competes with radioligand binding at
Sig1-Rs and serotonin transporters with high to moderate afﬁnities
and with lower afﬁnities to sites on NMDAR and NA transporters
(Table 1). DM did not compete with the agonist binding of 3H-
epibatidine to the neuronal acetylcholine nicotinic receptor in this
study, although functional antagonism has been reported (discussed
in Section 3.6). The screening data also show weak potential interac-
tions of DMwith adrenergic α1D receptors (Ki = 830 nM), rat calcium
L-type (benzothiazepine) channels (Ki = 2800 nM for enhanced bind-
ing), human adrenergic α1A receptors (Ki = 3000 nM), and rat sodium
(Site 2) channels (57% inhibition with 10,000 nM DM). With weak
radioligand binding Ki values of over 1000 nM, these interactions are
unlikely to be clinically relevant; however, functional studies are lackingRadioligand Ki of radioligand Reference
[3H]paroxetine, 0.2 nM 0.2 nM Werling et al., 2007b
[3H]pentazocine, 2 nM 5 nM Werling et al., 2007b
[3H]nisoxetine, 2 nM 0.7 nM Pubill et al., 1998
[3H]MK-801, 0.5 nM 1.6 nM Jaffe et al., 1989
[3H]MK-801, 3 nM 1.6 nM Werling et al., 2007b
[3H]prazosin, 0.1 nM 0.1 nM (Kd) Avanir data on ﬁle
[3H]prazosin, 0.2 nM 0.15 nM (Kd) Avanir data on ﬁle
[3H]DTG, 2.5 nM 21 nM Chou et al., 1999
[3H]GR 125,743, 0.3 nM 0.24 nM Werling et al., 2007b
[3H]yohimbine, 2 nM 1.4 nM Werling et al., 2007b
[3H]mepyramine, 2 nM 1.5 nM Werling et al., 2007b
amate receptor, NT — not tested, NC — no signiﬁcant competition of radioligand binding
ata on ﬁle, obtained from Cerep, Celle l'Evescault, France, July 25, 2012.
l other sites (Avanir data onﬁle fromRicerca Biosciences, Taipei, Taiwan, November 2010).
1B,α2A, β1, β2, bradykinin B1, B2, calcium channel dihydropyridine, calcium channel N-
ctor, GABAA ﬂunitrazepam, GABAA muscimol, GABAB1A, glucocorticoid, glutamate kainate,
tamine H1, H2, H3, imidazole I2, interleukin IL-1, leukotriene, melatonin MT1, muscarinic
factor, potassium channel KATP, potassium channel hERG, prostanoid EP4, purinergic P2X,
e, dopamine transporter.
centrations and without functional pharmacologic testing is not known and needs conﬁr-
lly useful serotonin 5-HT1B agonists (sumatriptan, dihydroergotamine) have Ki values for
rgic α1D antagonist BMY 7378 has a Ki value for radioligand binding of 0.4 nM (Goetz
174 C.P. Taylor et al. / Pharmacology & Therapeutics 164 (2016) 170–182(see additional discussion in Section 4 and also Section 3.7 below, cation
channel blocking actions), and therefore, additional studies will be re-
quired to determine the relevance of these targets to DM/Q
pharmacology.
3.2. Inhibition of serotonin reuptake
Serotonin is a monoamine neurotransmitter involved in the regula-
tion of mood and behavior with 14 known receptors in humans
(Donaldson et al., 2013). Serotonin reuptake transporters are a major
site of action of many antidepressant drugs. In an in vitro functional
study (Codd et al., 1995), DM potently inhibited serotonin reuptake
into rat brain synaptosomes with Ki = 23 nM (Table 2). Although we
could ﬁnd no experiments directly measuring serotonin concentrations
in the brain extracellular space with and without DM treatment
(e.g., microdialysis studies), an experiment in rats showed decreased
brain concentrations of the serotonin metabolite 5-hydroxyindoleacetic
acid after DM doses of 20 to 40 mg/kg i.p., providing indirect evidence
of serotonin reuptake inhibition (Ahtee, 1975). Additionally, an in vivo
functional study of rats with 6-hydroxydopamine lesions to the
substantia nigra (a rat model of Parkinson's disease) showed that DM
(45 mg/kg i.p.) partially reversed levodopa-induced abnormal involun-
tarymovements, an effect thought to bemediated, at least in part, by se-
rotonin 5-HT1A autoreceptor stimulation (Paquette et al., 2012). This
effectwas reversed by a selective serotonin 5-HT1A antagonist and is con-
sistentwithDMacting indirectly on 5-HT1A receptors via inhibition of se-
rotonin reuptake. Furthermore, in a model of serotonin syndrome in
rabbits, Sinclair (1973) showed that DM (5 mg/kg i.v.) increased body
temperature by rapidly enhancing the action of the monoamine oxidase
inhibitors phenelzine or nialamide, effects attributed to serotonin reup-
take inhibition of DM. Similar ﬁndings have been observed in humans
when DM (without quinidine) was co-administered with monoamine
oxidase inhibitors (Rivers & Horner, 1970; Sovner & Wolfe, 1988), con-
sistent with DM or its metabolites increasing brain serotonin concentra-
tions via serotonin reuptake inhibition.
3.3. Agonist action at sigma-1 receptor sites
The Sig1-R gene, SIGMAR1, is highly conserved across species
(Hanner et al., 1996; Kekuda et al., 1996; Pan et al., 1998; Seth et al.,
1998) and encodes for a transmembrane protein located in the
endoplasmic reticulum (ER) of neurons and other cells (Hayashi,
2015). It exhibits no homology to other mammalian proteins (Hanner
et al., 1996), representing a unique structural class of protein that is
distinct from G-protein coupled receptors, ligand-gated ion channels
and neurotransmitter transporters. Contrasting with the common con-
ﬁguration of neurotransmitter receptors, the Sig1-R binding site is ini-
tially located in the inner or luminal surface of the ER membrane
(Hayashi, 2015). The Sig1-R functions as a ligand-activated chaperone
and can modulate the activity of classical neurotransmitter systems
and signaling cascades through direct or indirect interactions with ion
channels, receptors, and other cellular proteins and components
(Hayashi & Su, 2007; Su et al., 2010; Hayashi, 2015). In the brain,Table 2
In vitro functional pharmacology data for dextromethorphan and its metabolite dextrorphan.
Test Tissue source Test method
5-HT reuptake inhibition Rat brain synaptosomes [3H] 5-HT uptake (Ki
Sig1-R agonist activity
(spreading depression)
Rat neocortical brain slice Neuroimaging and e
recordings
Norepinephrine reuptake inhibition Rat brain synaptosomes [3H]NA uptake (Ki)
NMDAR ion channel
(uncompetitive antagonism)
Mouse neocortex cultured
neurons
Voltage clamp (IC50)
Nicotinic α3β4 antagonism Xenopus oocytes Voltage clamp (IC50)
Nicotinic α4β2 antagonism Xenopus oocytes Voltage clamp (IC50)
NA — noradrenaline; 5-HT — serotonin.Sig1-Rs are found in areas such as the cerebellum, brainstem, neocortex,
striatum, and hippocampus (Gundlach et al., 1986; McLean & Weber,
1988; Bouchard & Quirion, 1997).
The interaction between DM and Sig1-Rs in the brain was ﬁrst de-
scribed in the 1980s. High afﬁnity ligand binding sites for DM were
identiﬁed in the rodent brain and were subsequently characterized as
recognition sites for other Sig1-R ligands (Canoll et al., 1989; Klein &
Musacchio, 1989; Musacchio et al., 1989). Using more selective ligands
that have since been developed, DMhas been conﬁrmed to bind to Sig1-
Rs, but not sigma-2 receptors, with signiﬁcant afﬁnity (Shin et al., 2007;
Werling et al., 2007a; Fishback et al., 2012). In the presence of 400 nM
DM, radioligand binding of the high-afﬁnity Sig1-R agonist [3H](+)-
pentazocine occurred with reductions in both Kd and Bmax, suggesting
complex interactions with Sig1-Rs which may involve competitive as
well as non-competitive binding (Nguyen et al., 2014).
A number of studies indicate that DM acts, at least in part, as an ag-
onist at Sig1-Rs. For example, selective Sig1-R antagonists can mitigate
the effects of DM in various preclinical models. The hallmark antitussive
effect of DM can be attenuated by the Sig1-R antagonist BD1047 in a
guinea pig citric-acid cough model (Brown et al., 2004). The previously
reported anticonvulsant and neuroprotective effects of DM also are re-
duced by Sig1-R antagonists such as BD1047 (Kim et al., 2003; Shin
et al., 2005, 2007). Also, in rat neocortical brain slices in vitro, DM
prevented spreading depression, and this was reversed with Sig1-R an-
tagonists in this experiment (Anderson & Andrew, 2002). Finally, DM
elicited antidepressant-like effects in the mouse forced swim and tail
suspension tests, which were attenuated by the Sig1-R antagonist
BD1063 or the AMPA receptor antagonist NBQX (Nguyen et al., 2014;
Nguyen & Matsumoto, 2015).
Other Sig1-R agonists elicit antitussive effects (Brown et al., 2004),
convey neuroprotective actions (Nguyen et al., 2015; Ruscher and
Wieloch, 2015), and also produce antidepressant effects in animal
models (Bermack & Debonnel, 2005; Fishback et al., 2010; Hashimoto,
2015). In contrast, knockdown or knockout of Sig1-Rs can promote
cell death and damage (Wang & Duncan, 2006; Hayashi & Su, 2007;
Ha et al., 2011; Mavlyutov et al., 2011; Mori et al., 2012; Vollrath et al.,
2014; Bernard-Marissal et al., 2015) or a depressive-like behavioral
phenotype (Sabino et al., 2009; Chevallier et al., 2011; Sha et al., 2015).
Some effects of Sig1-R agonists have been reported to occur through
the modulation of glutamatergic mechanisms (Martina et al., 2007;
Balasuriya et al., 2013; Pabba et al., 2014; Nguyen & Matsumoto,
2015) and other well established targets that become engaged under
pathological conditions (Bermack & Debonnel, 2005; Maurice & Su,
2009; Nguyen et al., 2014; Hashimoto, 2015).
Speciﬁc cellular mechanisms through which Sig1-Rs may mediate
the effects of DM have not yet been determined. Systematic studies
are still needed to assess the manner and extent to which Sig1-Rs may
promote therapeutic actions of DM.
3.4. Inhibition of noradrenaline reuptake
DM has been reported to inhibit [3H]-NA uptake into rat brain syn-
aptosomes in vitro with a Ki value of 240 nM (Codd et al., 1995). ADM (nM) DX (nM) References
) 23 (Ki) 401 (Ki) Codd et al., 1995
lectrophysiological 10,000 nM blocked
spreading depression
Not available Chou et al., 1999
240 (Ki) 340 (Ki) Codd et al., 1995
550 (IC50) 72 (IC50) Trube & Netzer, 1994
700 (IC50) 1300 (IC50) Damaj et al., 2005
3900 (IC50) 3000 (IC50) Damaj et al., 2005
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1700 nM (Rogers & Lemaire, 1991). The values from these functional
studies show greater potency than the Ki for inhibition of radioligand
binding at NA reuptake sites (6000 to 14,000 nM) (Table 1), and the rea-
son for this discrepancy is not known. An investigation of DM (5mg/kg
i.p.) in non-anesthetized cats showed two-fold enhanced nictitating
membrane responses to direct application of both serotonin and NA,
suggesting that DM enhances the actions of both neurotransmitter
systems in vivo (Sinclair, 1973). However, conﬁrmatory studies of NA
reuptake blockade from DM in humans are lacking.3.5. Blockade of N-methyl-D-aspartate receptors
The NMDAR is one of three kinds of ionotropic glutamate recep-
tors, which together mediate most rapid excitatory neurotransmis-
sion in the brain (Dingledine et al., 1999; Purves et al., 2001).
NMDARs are cation channels that each contain four protein subunits.
Overall, NMDAR channels function in a manner similar to other
ligand-gated ion channels in allowing both sodium and potassium
ions to ﬂow. However, NMDARs also allow calcium to enter cells,
which, in turn, activates a number of processes inside of cells (Lau
& Zukin, 2007). NMDARs are unusual because their function requires
two different agonists (glutamate and also the co-agonists glycine or
D-serine). In addition, NMDARs have conductance that is enabled by
depolarization, which reduces blockade of the channel pore by mag-
nesium ions. Finally, NMDA receptors are required for multiple forms
of synaptic plasticity, including long-term potentiation (LTP) and
long-term depression (LTD) that are necessary for several kinds of
memory formation (Lau & Zukin, 2007).
Electrophysiology studies in isolated cells indicate that the DM
blockade of the NMDAR channel is more effective at voltages near the
resting potential of the neuronal membrane than at depolarizing volt-
ages. This voltage-dependent effect suggests that DM binds in an un-
competitive manner at a site deep within the ion channel pore, similar
to other NMDAR channel blockers (e.g., ketamine, phencyclidine, or
memantine) (Ferrer-Montiel et al., 1998).
The NMDAR channel blocking kinetics of DM and other uncompeti-
tive NMDAR antagonists are summarized in Table 3 (data from Parsons
et al., 1995). Rapid unbinding from the channel open state and a favor-
able tolerability proﬁle differentiate DM and memantine (Bresink et al.,
1995; Parsons et al., 2007) from high-afﬁnity, slow-unblocking ligands
such as phencyclidine, ketamine or MK-801, the use of which is associ-
atedwith characteristic side effects of confusion, agitation,memory loss
and hallucinations (Lipton, 2006; Parsons et al., 2007). This point ofTable 3
Potency and kinetics of channel blocking drugs on neuronal NMDA receptors.
Drug MK-801 binding Ki
(nM)
Patch clamp IC50
(nM)
Kon at IC50
(ms)
Koff
(s−1)
MK-801 2.6 140 34,000 0.005
Phencyclidine 500 1000 13,750 0.050
Dextrorphan NTa 1300 4762 0.075
Ketamine 200 1600 1024 0.075
Dextromethorphan 780 6100 2125 0.179
Memantine 700 2300 820 0.200
Note: For radioligand binding, puriﬁed rat synaptic membranes were incubated with
[3H](+)-MK-801, and nonspeciﬁc binding was deﬁned with 10 μM MK-801. For patch
clamp recordings, isolated superior colliculus neurons from rat embryos were cultured
with serum-supplemented minimal essential medium until recording. Membrane poten-
tial was held at−70mV, and voltage-clamped responses to 200 μMNMDAwere obtained
with and without the indicated drug present. Patch clamp IC50 values were determined
with at least three concentrations of test drug producing between 15% and 85% inhibition.
The rates of drug association (Kon) and dissociation (Koff) were determined by measuring
the rate of inhibition and recovery upon drug application and withdrawal.
a NT—not tested. Data reprinted andadapted fromParsons et al. (1995)with permission
from Elsevier.differentiation is further supported by ﬁndings in rodents where DX,
phencyclidine, and ketamine were found to cause large increases in
spontaneous locomotor activity (a dissociative behavioral effect medi-
ated by NMDAR block), whereas DM was found to cause a modest in-
crease in locomotion at high doses only, which the authors stated
could be a result of metabolism to DX (Szekely et al., 1991; Danysz
et al., 1994). The 20% reduction of sustained NMDAR responses in cul-
tured neocortical neurons elicited with 100 nM DM (Trube & Netzer,
1994), and the fact that the unbound concentration of DM in DM/Q-
treated humans ranges from 56 nM to 96 nM, suggest that DM treat-
ment with therapeutic doses results in only a fractional block of
NMDAR channels.
In addition to the synaptically-evoked NMDAR currents, NMDAR
currents from non-synaptic glutamate (at near-resting membrane
potential) occur spontaneously and are thought to arise mostly from
glutamate released from glial cells via nonvesicular mechanisms
(Le Meur et al., 2007; Hardingham & Bading, 2010; Oh et al., 2012;
Papouin & Oliet, 2014). Non-synaptic NMDAR currents may alter the
functional input–output relationship of cortical pyramidal neurons
(Sah et al., 1989) and also may be involved in NMDAR-dependent cell
death and neurodegenerative diseases, as well as the pathophysiology
of depression (Okamoto et al., 2009; Hardingham & Bading, 2010;
Miller et al., 2014). Non-synaptic NMDARs are relatively enriched
in the subunit GluN2B and are preferentially activated by the co-
transmitter glycine rather than by D-serine (Papouin & Oliet, 2014).
Furthermore, activation of nonsynaptic NMDARs appears to be
necessary for long-term depression (LTD), but not for long-term
potentiation (LTP) (Papouin & Oliet, 2014). Studies of the kinetically
slow NMDA blocker MK-801 (Le Meur et al., 2007) and the kinetically
fast compound memantine (Leveille et al., 2008; Xia et al., 2010)
indicate that the competitive NMDAR antagonist d-(−)-2-amino-5-
phosphonopentanoic acid (AP-5) has equal potency to block spontane-
ous non-synaptic and synaptic NMDAR currents. However, MK-801
(applied under conditions that activate synapses) preferentially blocks
synaptic NMDARs, but memantine (and presumably also DM), due to
rapid off-binding kinetics, more selectively blocks non-synaptic
NMDARs (Parsons et al., 2007; Leveille et al., 2008; Hardingham &
Bading, 2010; Xia et al., 2010). The impact of DM/Q treatment on
NMDARs needs to be elucidated in future research to assess, for exam-
ple, whether DM/Q produces fractional blockade of NMDARs at doses
used therapeutically, and particularly at hyperpolarized membrane
voltages and at non-synaptic NMDARs.
Furthermore, like memantine, DM/Q treatment may be slightly
more effective at blocking NMDARs comprised of certain subunit
combinations (GluN1/GluN2B or GluN1/GluN2C) than others (GluN1/
GluN2A) (Dravid et al., 2007). In addition, the subunit selectivity of
some NMDAR antagonists increases when physiological concentrations
of magnesium ions (1mM) are present (Kotermanski & Johnson, 2009).
This same effect might somewhat increase the selectivity of other chan-
nel blockers including DM and DX for GluN2C- and GluN2D-containing
NMDARs in comparison to GluN2B- and GluN2A-containing NMDARs.
GluN1/GluN2A receptors are the most common NMDAR subtype
expressed in the neocortex (Table 4).
Action at NMDARs has been used to explain various therapeutic ef-
fects of DM in humans (Verhagen Metman et al., 1998; Ilkjaer et al.,
2000; Duedahl et al., 2005; Wankerl et al., 2010; Ehret et al., 2013);
however, in each of these cases, other receptors could also be important.
Furthermore, in humans theNMDAR blockwith DMadministered alone
may result from the metabolite DX rather than from unchanged DM.
Because DM has faster dissociation kinetics than DX at NMDAR, the
presumed NMDAR-mediated actions of DM given alone should be
reappraised with DM/Q, which provides substantially higher DM
plasma concentrations and correspondingly lower DX concentrations
(see comparative NMDAR kinetics of DM andDX in Table 3). The clinical
relevance of NMDAR interactions even with the altered ratio of DM to
DX remains unclear.
Table 4
Pharmacological block of cation channels by dextromethorphan.
Cation channel type Tissue source DM potency Reference
GluN1/GluN2A NMDA receptors Recombinant cells IC50 = 11,000 nM Dravid et al., 2007
Serotonin 5HT3 receptor channel current Rat nodose ganglion neurons IC50 ~ 10,000 nM Ishibashi et al., 2006
Glycine inhibitory receptor current Guinea pig nucleus tractus solitarius neurons IC50 ~ 3000 nM Takahama et al., 1997
GTPγS activated GIRK potassium current Rat raphe neurons IC50 ~ 10,000 nM Ishibashi et al., 2000
Kv1.2 and Kv1.3 potassium channel electrophysiology Cloned channels expressed in Xenopus IC50 = 13,000 nM Lee et al., 2011
Ca2+ ﬂuorescence via voltage-gated Ca2+ channels Cultured rat hippocampal neurons IC50 ~ 20,000 nM Church et al., 1991
Ca2+ inﬂux via voltage-gated Ca2+ channels Rat brain synaptosomes IC50 = 48,000 nM Carpenter et al., 1988
Voltage-gated Ca2+ current electrophysiology Mouse cortex neurons IC50 = 50,000 nM Netzer et al., 1993
Na+ current electrophysiology Cultured mouse cortex neurons IC50 = 90,000 nM Trube & Netzer, 1994
K+ induced 45Ca2+ uptake (L-type channels) PC12 cells IC50 = 100,000 nM Carpenter et al., 1988
AMPA currents Cultured mouse cortex neurons IC50 N 10,000 nM Trube & Netzer, 1994
Note— None of the actions described in this table occur with free concentrations of DM found in plasma with DM/Q therapy (Fig. 4, “Cation channel block”). Therefore, none of these ac-
tions are thought to be relevant for therapy with DM/Q. Readers are referred to the cited papers for details of methods used.
176 C.P. Taylor et al. / Pharmacology & Therapeutics 164 (2016) 170–1823.6. Antagonist action at nicotinic α3β4 receptor ion channels
Two reports indicate that DM is a functional antagonist of nicotinic
acetylcholine (ACh) receptors (Hernandez et al., 2000; Damaj et al.,
2005), particularly those comprised of α3β4 subunits (IC50 value of
700 nM forα3β4 recombinant receptors vs. 3900 nM forα4β2 receptors
expressed in Xenopus oocytes) (Damaj et al., 2005). Although DM is a
functional antagonist it does not compete with the agonist binding
site (Hernandez et al., 2000;Werling et al., 2007b). Nicotinic ACh recep-
tors are pentameric ion channelswith several different subunits that are
permeable to sodium and potassium ions. In addition, there are differ-
ent subtypes of each subunit. Channels consisting of both α3 and β4
subunits also are permeable to calcium ions. This subtype of nicotinic
ACh receptor is present on the presynaptic terminals of noradrenergic
neurons in the neocortex, as shown by the block of NA release from
rat neocortical synaptosomes by the selective nicotinic cone snail
toxin α-AuIB (Kulak et al., 2001). There also is evidence that the α3β4
nicotinic subtype is the predominant mediator of ACh-induced adrena-
line release from adrenal chromafﬁn cells (Campos-Caro et al., 1997;
Tachikawa et al., 2001).
The selectivity and potency of DM at nicotinic ACh receptors is sim-
ilar to that of mecamylamine, a nicotinic ACh receptor antagonist that is
somewhat selective for α3β4 receptors. Mecamylamine reduces release
of adrenaline and NA from isolated rat adrenal glands, suggesting
potential moderation of some behavioral effects of stress in vivo
(Yokotani et al., 2002). It is interesting that mecamylamine, in addition
to its use as an antihypertensive drug, also has been used at lower dos-
ages as therapy for Tourette's syndrome (Sanberg et al., 1998). Although
not effective to reduce Tourette's symptoms, one placebo-controlled
trial showed that mecamylamine was associated with a decrease in
sudden mood changes in young patients (Silver et al., 2001). Meca-
mylamine also reduced cue-induced craving in cocaine addicts
(Reid et al., 1999) and attenuated the somatic stimulant effects of alco-
hol (Blomqvist et al., 2002; Chi & de Wit, 2003) and tobacco use in
humans (Rose et al., 1994). However, in a clinical trial, the mecamyl-
amine enantiomer, dexmecamylamine, was not different from placebo
in a multicenter add-on study of treatment for major depressive disor-
der (Vieta et al., 2014). Whether DM/Q treatment would have effects
similar to mecamylamine is currently not known.
The role of α3β4 nicotinic ACh receptors in reducing drug-seeking
behaviors has been discussed in several animal pharmacology papers
(Glick et al., 2002; Taraschenko et al., 2005) and in papers cited therein.
Other studies independently suggest that the nicotinic α3β4 subtype
is important for modulating ACh release in brain areas known to be
important for drug addiction (Grady et al., 2009).
Animal studies provide evidence that DM acts at nicotinic receptors
in vivo. DM potently reduced analgesia from exogenous nicotine in the
mouse tail-ﬂick test (Damaj et al., 2005). DMwas effective at lower dos-
ages with s.c. dosing (0.8 mg/kg) thanwith i.p. dosing (2.4mg/kg), sug-
gesting that DM (less subject to ﬁrst-pass metabolism with s.c. dosing),and not DX, was the active moiety. The effect of DMwas not considered
to be due to an NMDAR antagonist action sinceMK-801 had no effect in
this experiment. Although this result does not speak to possible analge-
sic actions of DM in mice in the absence of exogenous nicotine, it does
suggest that DM reduces nicotinic responses in this model at low
dosages.
In a placebo-controlled study in humans undergoing knee surgery,
preoperative administration of DM (30 mg p.o.) signiﬁcantly dimin-
ished tourniquet-induced hypertension and tachycardia, effects associ-
ated with sympathetic activation (Yamashita et al., 2004). Whether
DM or DM/Q act to reduce sympathetic tone through α3β4 nicotinic
receptor antagonism in humans and whether α3β4 antagonism has
relevance for the therapeutic effect of DM/Q in the treatment of PBA
requires further study.
3.7. Action of dextromethorphan at other known targets
DMhas been reported in various in vitro studies to block several dif-
ferent cation channels including voltage-gated sodium channels, potas-
sium channels, calcium channels and some ligand-gated ion channels
such as serotonin 5-HT3 receptors (Table 4). However, most of these
IC50 values are in the range of 10,000 nM and greater. For this reason,
it is unlikely that even fractional channel block is obtained with the
free DM concentrations that are achieved in the brain with clinical
DM/Q treatment. Since the extrapolated values for unbound plasma
concentrations of DM during DM/Q therapy are 35 to 120 nM, it is
very unlikely that receptor actions with Ki or IC50 values of ≥3000 nM
in vitro would have signiﬁcant clinical impact in humans. Therefore, it
is also unlikely that recommended therapeutic doses of DM/Q would
have any pharmacological activity at the targets in Table 4 despite the
actions of DM at each of these sites in vitro.
DM inhibits glycine-gated chloride channels, which are blocked by
DM with IC50 and Kd values that are both near 3000 nM (Takahama
et al., 1997). The action of DM at inhibitory glycine receptors is unlikely
to be clinically relevant because of the relatively high concentrations
needed.
DM is a lipophilic molecule with an ionizable amine at one end. This
kind of molecule is partially permeable to several different cation
channels, allowing open-channel block of various ion channels without
much selectivity (Catterall, 1994; Gao et al., 2005). One subtype of
NMDAR (GluN1/GluN2A, the most common in forebrain) is also
shown in Table 4 as less likely to be blocked by DM.
4. Original analysis: estimation of
dextromethorphan effects in brain based on in vitro
function and unbound plasma dextromethorphan concentrations
There are no in vivo human positron emission tomography (PET) or
single-photon emission computed tomography (SPECT) data to directly
assess occupancy of various relevant receptors in the brain following
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mate receptor occupancy at individual molecular drug targets. The fol-
lowing analysis uses calculated unbound plasma, extrapolated “CSF”,
or “unbound brain” drug concentrations of DM and DX relevant in the
treatment of PBA for comparison with in vitro functional pharmacolog-
ical results (Table 2) to arrive at an estimate ofwhich targetsmay be im-
portant for DM effects in the clinical treatment of PBA. Recent analyses
of the pharmacology of drugs acting within the brain at more than
one molecular site have compared clinically determined unbound plas-
ma drug concentrations to in vitro data on the functional Ki or IC50
values of the same drug (Derijks et al., 2008; Brynne et al., 2013). A sim-
ilar approach is used in the present analysis to distinguish receptor/
transporter interactions that are clinically relevant from those that
may occur only at concentrations greater than those encountered
clinically in treating PBA.
DM plasma concentrations have been measured in several clinical
trials of DM/Q, and can be estimated in rat ormousemodels by compar-
ing doses with pharmacokinetic studies in these species (unpublished
Avanir mouse pharmacokinetic study; Wu et al., 1995). Drug binding
to plasma proteins also has been measured both in rats and in humans,
and the fraction unbound (45% in rats and 35% in humans) does not
vary with DM concentration (Witherow & Houston, 1999; Avanir
Pharmaceuticals, Inc., 2010). Unbound DM plasma concentrations are
consistent with values found experimentally in human CSF (Fig. 3).
Therefore, extrapolated plasma concentrations of unbound DM during
DM/Q therapy can be compared with DM concentrations in various
in vitro functional studies (Fig. 4). At DM/Q concentrations measured
during clinical treatment for PBA, DM is estimated to be present at
brain interstitial ﬂuid concentrations sufﬁcient to inhibit serotonin and
NA reuptake, partially block NMDARs, and partially blockα3β4 nicotinic
receptor channels. These conclusions are based on direct interactions of
drugs at extracellular receptors and do not consider the potential forFig. 4. Effective concentrations of DM (from in vitro pharmacology studies, top) are compare
(middle) and clinical trials of DM/Q (bottom). In vitro pharmacological IC50 values (bla
noradrenaline (NA) uptake (Codd et al., 1995); NMDAR block in cultured neurons (Trube & N
against rat spreading depression (Anderson & Andrew, 2002); cation channel block (see Ta
represent IC50 or Ki (vertical bar) with 15-fold ranges greater or less, illustrating the dynamic
the following references: nicotine block (Damaj et al., 2005); DBA/2 seizures (Chapman & M
drug concentrations in mice were determined from ED50 doses, pharmacokinetic peak plasm
exposure (free concentrations) was determined by accounting for 65% of drug bound nonspe
pale blue box shows the range of free DM in human plasma (Cmax) from clinical trials wh
represent free drug concentrations following clinical trials of DM/Q. For 20 mg/10 mg and 30
from unpublished Avanir pharmacokinetic trial 13-AVR-134.drugs to bind to intracellular receptors during early exocytotic path-
ways of cellular protein processing (Lester et al., 2012). Although DM
reaches sufﬁcient concentrations to bind to the intracellular Sig1-R pro-
tein, it is less clear, based on current information, whether sufﬁcient
concentrations are reached for it to act as a functional Sig1-R agonist.
It is unlikely that DM would bind signiﬁcantly to serotonin 5-HT1B re-
ceptors (Table 1) or block other cation channels (see discussion in
Section 3.7) except in cases of overdose.
5. Discussion and conclusions
Although DM may be best known as an NMDAR channel blocker,
several additional receptor targets may contribute to its pharmacody-
namic and therapeutic effects. DM receptor interactions based on
in vitro experimental results and DM plasma concentrations achieved
in clinical studies of DM/Q allow us to identify which of these may be
of greatest clinical relevance (Fig. 5). Our analysis suggests that DM
acts as a serotonin reuptake inhibitor and as a norepinephrine reuptake
inhibitor at standard clinical doses of DM/Q andwould also be expected
to provide fractional block of NMDAR channels with kinetics allowing
more rapid dissociation and better tolerability than drugs like phency-
clidine. Partial NMDARblockade could account for decreases in late neo-
cortical excitability seenwith DM/Q treatment, asmeasured by auditory
evoked potentials in persons with PBA (Haiman et al., 2009). Addition-
ally, DM may provide partial block of nicotinic ACh receptor channels,
particularly of the α3β4 subtype. This subtype-selective nicotinic
blocking action may contribute to reduced cholinergic activation fol-
lowing emotionally relevant stimuli. Finally, DMmay act as a Sig1-R ag-
onist resulting in the modulation of one or more neuronal ion channels,
monoamine and glutamate-mediated transmission, or other intracellu-
lar actions (Maurice & Su, 2009) which could be relevant for PBA
treatment. Data with DM for other potential targets (e.g., block ofd to free plasma drug concentrations (equal to CSF concentrations) from mouse studies
ck horizontal bars) are from the following references: serotonin (5-HT) uptake and
etzer, 1994); nicotinic receptor subtype α3β4 block (Damaj et al., 2005); Sig1-R efﬁcacy
ble 4). The range of concentrations shown for in vitro function (thick horizontal bars)
range between ~10% and 90% effect from the Hill equation. In vivo mouse data are from
eldrum, 1989); antidepressant-like action (forced swim test) (Nguyen et al., 2014). Free
a concentrations, and 55% plasma binding in rats (Witherow & Houston, 1999). Human
ciﬁcally to plasma proteins in clinical samples (Avanir Pharmaceuticals, Inc., 2010). The
en given at the dose speciﬁed (DM dose/Q dose given twice daily, BID). Clinical data
mg/10 mg BID doses, data are the 95% conﬁdence interval of mean Cmax. Human data are
Fig. 5. Summary of DM molecular sites of drug action in human brain. (A) DM inhibits the action of serotonin transporters and NA transporters similar to a well-known class of drugs.
(B) DM binds as a readily-reversible blocker of NMDA-type glutamate receptors at a site (DM) similar to those of memantine, ketamine and phencyclidine and not far from the site of
endogenous Mg2+ ion binding. At this site, DM prevents permeant ions (sodium, calcium and potassium) from producing ionic currents and also limits increases in intracellular
calcium concentration. However, the dissociation rate of DM from NMDA receptors is quite rapid, which may be important for tolerability in patients (see text for details).
Figure adapted from Parsons et al. (2007) with permission from Elsevier. (C) DM blocks nicotinic acetylcholine-gated ion channels by binding within the channel pore. Although DM
blocks several subtypes of nicotinic receptors, its action is somewhat selective for receptors composed of α3 and β4 subunits. This binding prevents the inﬂux of Na+ and Ca2+ and
reduces excitation of neurons from acetylcholine. Figure adapted from Changeux (2010) with permission from Elsevier. (D) DM acts as a Sig1-R agonist in vitro, and animal data also
support this ﬁnding (antidepressant-like and anticonvulsant activity are blocked by sigma antagonists). The molecular changes that result from Sig1-R actions of DM are not clear. This
ﬁgure shows the Sig-1R protein chaperone as a cytosolic and plasma membrane signaling molecule. At the interface between endoplasmic reticulum (ER) and mitochondrion
(MAM or mitochondrion-associated membrane), activation by Sig-1R agonists causes Sig-1R to dissociate from an ER chaperone (BiP). Subsequently, Sig-1R associates with the
inositol trisphosphate receptor (IP3R) to enhance Ca2+ release from ER into mitochondria, modulating mitochondrial function. If stimulated by high concentrations of Sig1-R agonists
(10× the radioligand binding Ki value) or in the presence of strong ER stress, Sig1-Rs rapidly migrate from MAM and become associated with ion channels at the plasma membrane
where they modulate channel expression and function. In different cell types, these Sig-1R associated proteins include NMDA receptors, ion channels (NaV1.5, ASIC, hERG, Kv1.4,
Kv1.5, SK) and potentially other proteins. Figure adapted from Su et al. (2011).
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Fig. 5 (continued).
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minimal or insigniﬁcant interactions of DM/Q at currently used doses.
Additional study will be required to conﬁrm the extent and time
course of DM receptor occupation at various sites in the human brain,
and the extent to which activity at each of these sites may contribute
to the clinical efﬁcacy of DM/Q for PBA. Future experimental studies
with speciﬁc positron emitter tracer ligands or similar methods in
human subjects treated with DM/Q would be particularly useful to
test the extent that DM binds to these receptor targets in human
brain. Such approaches have been used previously to study human
drug receptor occupancy to various receptor and transporter targets
in vivo (Mamo et al., 2007; Pike, 2009).
The receptor sites of DM/Q treatment in the brain thatwe have iden-
tiﬁed are consistent with the proposed pathophysiology of PBA. The de-
tails of pathophysiology in PBA are beyond the scope of this review.
However, it is interesting that the receptors that we have identiﬁed as
likely targets of DM/Q treatment are among those that have been impli-
cated based on the functional anatomy of the brainstemand descending
pathways to the brainstem that are relevant for PBA (Parvizi et al., 2001;
Parvizi et al., 2009; Lauterbach et al., 2013; Cummings et al., 2015).In summary, our analysis indicates that the addition of quinidine to
dextromethorphan greatly increases the amount of circulating free
dextromethorphan and decreases the metabolite dextrorphan, to the
extent that the main active drug moiety with DM/Q treatment in
humans is dextromethorphan. Furthermore, we have shown that the
amount of free dextromethorphan achieved with DM/Q treatment is
sufﬁcient to signiﬁcantly inhibit serotonin and noradrenaline trans-
porters in human brain and also sufﬁcient to bind at Sig1-R and to
partially block ion channels gated by certain NMDAR and nicotinic
acetylcholine receptors. One or more of these potential therapeutic tar-
gets are likely to be involved in the clinical actions of DM/Q treatment.Conﬂict of interest statement
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